| Bioactivity | RRx-001, a hypoxia-selective epigenetic agent and studied as a radio- and chem-sensitizer, triggers apoptosis and overcomes drug resistance in myeloma. RRx-001 exhibits potent anti-tumor activity with minimal toxicity[1]. RRx-001 is a dual small molecule checkpoint inhibitor by downregulating CD47 and SIRP-α[2]. RRx-001 is a potent inhibitor of G6PD and shows potent antimalarial activity[3]. | ||||||||||||
| Invitro | RRx-001 (0-5 μM, 24 hours) inhibits MM cells growth and overcomes resistance to novel and conventional therapies[1]. RRx-001 blocks migration of MM cells and associated angiogenesis[1]. RRx-001 induces significant G1 phase growth arrest, with concomitant decrease in S phase. RRx-001 triggers significant apoptosis in MM cells[1]. RRx-001 inhibits DNA methylation by downregulating DNA methytransferases[1]. RRx-001 and the supernatant of RRx-001-treated macrophages downregulates CD47 on tumor cells and SIRPα on macrophages[2]. Cell Viability Assay[1] Cell Line: | ||||||||||||
| Name | RRx-001 | ||||||||||||
| CAS | 925206-65-1 | ||||||||||||
| Formula | C5H6BrN3O5 | ||||||||||||
| Molar Mass | 268.02 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|